UMBRIA BIOENGINEERING TECNOLOGIES SOCIETA A RESPONSABILITA LIMITATA

Their core work

UBT SRL is an Italian bioengineering SME that develops microwave-based medical imaging devices, with their flagship product MammoWave — a non-ionizing breast cancer screening system using ultra-high sensitivity microwave technology instead of X-ray mammography. Beyond their core medical device work, they contribute expertise in radio-frequency engineering, body-centric wireless communications, and wearable sensor systems. Their work bridges the gap between advanced RF/microwave physics and real clinical applications, particularly in safe, radiation-free diagnostic imaging.

What they specialise in

How they've shifted over time

UBT started their H2020 journey (2017-2018) focused squarely on commercializing their MammoWave breast imaging device, progressing from SME Instrument Phase 1 feasibility to Phase 2 full development — a classic deep-tech startup trajectory. From 2020 onward, they broadened into fundamental research areas: body-centric wireless communications (ROVER) and RF spintronics for neural computing (RadioSpin), both as participants rather than coordinators. This shift suggests a company that secured its core product pipeline and is now expanding its RF expertise into adjacent scientific domains, likely building capability for next-generation devices.

UBT is evolving from a single-product medical device company into a broader RF bioengineering firm, with growing interest in wearable health monitoring and advanced RF computing — expect future work at the intersection of these fields.

How they like to work

UBT shows a balanced profile: they led both MammoWave projects as coordinator (demonstrating they can manage EU consortia) and joined ROVER and RadioSpin as a contributing partner (showing they can integrate into larger teams). With 20 unique partners across 11 countries from just 4 projects, they build wide rather than deep networks — no sign of repeated partner clusters. This makes them an accessible and experienced partner for new consortia, comfortable in both leadership and specialist roles.

UBT has built a notably broad network for an SME of its size, collaborating with 20 distinct partners across 11 countries in just 4 projects. Their reach spans well beyond Italy, reflecting strong European connectivity through both their coordinated medical device projects and their participation in international research consortia.

What sets them apart

UBT occupies a rare niche: they are a small company with deep RF/microwave physics expertise applied directly to medical imaging, a space typically dominated by large multinationals. Their successful progression through both SME Instrument phases for MammoWave demonstrates a validated path from lab to market. For consortium builders, they offer the combination of hands-on RF hardware engineering, clinical application experience, and proven ability to coordinate EU projects — an unusual package for an SME.

Highlights from their portfolio

• MammoWave
  Flagship product: received €1.44M across Phase 1 and Phase 2 SME Instrument funding to develop a radiation-free microwave breast cancer screening device — UBT coordinated both phases.
• RadioSpin
  Largest single EC contribution (€673K as participant) in a frontier research project combining spintronics with deep learning via RF neuron networks, signaling UBT's expansion into advanced computing.
• ROVER
  MSCA-RISE project extending UBT's RF expertise into body-area networks, wearable sensors, and human-centric localization — bridges their medical device roots with broader health monitoring.